<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04580498</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-1701-II-205</org_study_id>
    <nct_id>NCT04580498</nct_id>
  </id_info>
  <brief_title>A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLC</brief_title>
  <official_title>An Open-label, Multicenter Phase II Clinical Trial of SHR-1701 With or Without Chemotherapy in the Treatment of Unresectable Stage III Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to evaluate the efficacy and safety of SHR-1701 with or without&#xD;
      chemotherapy in the treatment of unresectable stage III non-small cell lung cancer&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 15, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>From the initiation of the first dose to 3 years</time_frame>
    <description>Objective response rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EFS</measure>
    <time_frame>From the initiation of the first dose to 3 years</time_frame>
    <description>event free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>From the initiation of the first dose to 3 years</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EFS rate</measure>
    <time_frame>From the initiation of the first dose to 3 years</time_frame>
    <description>event free survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TDDM</measure>
    <time_frame>From the initiation of the first dose to 3 years</time_frame>
    <description>time to death or distant metastasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events(AEs)</measure>
    <time_frame>From the initiation of the first dose to 90 days after the last dose</time_frame>
    <description>Incidence of treatment-related AEs</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">122</enrollment>
  <condition>Non-Small-Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR-1701+Paclitaxel+carboplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR-1701</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1701+Paclitaxel+carboplatin</intervention_name>
    <description>Drug: SHR-1701 30mg/kg Drug: Paclitaxel 175mg/m2 Drug: Carboplatin AUC 5</description>
    <arm_group_label>Treatment group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1701</intervention_name>
    <description>Drug: SHR-1701 30mg/kg</description>
    <arm_group_label>Treatment group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Voluntarily participate in the study and sign the informed consent form;&#xD;
&#xD;
          -  18 to 70 years old, both male and female;&#xD;
&#xD;
          -  ECOG score: 0-1&#xD;
&#xD;
          -  histopathologically or cytologically confirmed, inoperable stage III squamous cell or&#xD;
             non-squamous cell lung cancer;&#xD;
&#xD;
          -  subjects who can provide fresh or archival tumor tissue;&#xD;
&#xD;
          -  Measurable lesions available;&#xD;
&#xD;
          -  Major organ function is basically normal;&#xD;
&#xD;
          -  Non-surgically sterile female subjects of childbearing age must have a negative serum&#xD;
             HCG test before randomization;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  histologically or cytologically confirmed mixed SCLC and NSCLC;&#xD;
&#xD;
          -  subjects who have malignant pleural effusion;&#xD;
&#xD;
          -  Previous systemic anti-tumor therapy for NSCLC;&#xD;
&#xD;
          -  Previous thoracic radiotherapy;&#xD;
&#xD;
          -  Subjects who participated in other clinical trials within 4 weeks or 5 drug&#xD;
             half-lives(whichever is shorter) before the first dose.&#xD;
&#xD;
          -  Systemic immunostimulant therapy before the first dose;&#xD;
&#xD;
          -  Systemic immunosuppressive therapy before the first dose or were expected to require&#xD;
             systemic immunosuppressive drugs during the study treatment;&#xD;
&#xD;
          -  Subjects with autoimmune diseases;&#xD;
&#xD;
          -  Other malignant tumors other than non-small cell lung cancer within 5 years before&#xD;
             screening;&#xD;
&#xD;
          -  Known or suspected interstitial pneumonia;&#xD;
&#xD;
          -  Other moderate to severe lung diseases that may interfere with the detection or&#xD;
             treatment of drug-related pulmonary toxicity and seriously affect respiratory&#xD;
             function;&#xD;
&#xD;
          -  Severe cardiovascular and cerebrovascular diseases;&#xD;
&#xD;
          -  Clinically significant bleeding symptoms or significant bleeding tendency within 1&#xD;
             month before the first dose;&#xD;
&#xD;
          -  Arteriovenous thrombotic events within 3 months before the first dose;&#xD;
&#xD;
          -  Positive HIV test;&#xD;
&#xD;
          -  Active hepatitis B or C;&#xD;
&#xD;
          -  Evidence of active tuberculosis infection within 1 year before the first dose;&#xD;
&#xD;
          -  Serious infection within 4 years before the first dose;&#xD;
&#xD;
          -  History of attenuated live vaccination 28 days before the first dose or expected to&#xD;
             receive attenuated live vaccination during the study;&#xD;
&#xD;
          -  Major surgeries other than diagnosis or biopsy within 28 days prior to first dose;&#xD;
&#xD;
          -  Previous or planned allogeneic bone marrow transplantation or solid organ&#xD;
             transplantation;&#xD;
&#xD;
          -  History of severe allergic reactions to other monoclonal antibodies/fusion proteins;&#xD;
&#xD;
          -  Allergic to any component of the randomized treatment regimen;&#xD;
&#xD;
          -  Female subjects who are pregnant, lactating, or planning to get pregnant during the&#xD;
             study period;&#xD;
&#xD;
          -  Subjects who has a known history of psychotropic drug abuse, alcoholism, or drug abuse&#xD;
&#xD;
          -  Presence of other conditions that, in the opinion of the investigator, would make&#xD;
             participation in this clinical trial inappropriate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yilong Wu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong General Hospital &amp; Guangdong Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wei Shi, MD</last_name>
    <phone>021-68868570</phone>
    <email>shiwei@hrglobe.cn</email>
  </overall_contact>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 28, 2020</study_first_submitted>
  <study_first_submitted_qc>October 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>October 6, 2020</last_update_submitted>
  <last_update_submitted_qc>October 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

